We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Asa3.0
Aspirin (low-dose) Research
Too few graded studies
3,949 peer-reviewed studies
Showing the 997 most recent of 3949 studies.
All 3952 database studies by type: RCT 3155 · Meta-Analysis 661 · Systematic Review 116 · Review 13 · Observational 4 · other 3
What the evidence says
Too few graded studies
Aspirin (low-dose) doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2009–2026.
Based on 993 studies · 313 meta-analyses · 621 RCTs
Confidence
High confidence
By outcome
Cardiovascular preventionGenuinely reduces recurrent cardiovascular events in people with established cardiovascular disease (secondary prevention; no benefit shown in healthy older adults) · Ongoing daily use
Too few graded studies345 studies
Safety profile
Too few graded studies85 studies
Healthy aging & mortality
Too few graded studies12 studies
Active research area
581 studies in the last 5 years · Latest meta-analysis: 2026
200920172026
1Meta-Analysis2026
In plain English: It is not possible to draw definitive conclusions or outline specific implications for the routine use of aspirin for CRC primary prevention based on the current evidence.
Cai Z et al. · The Cochrane database of systematic reviews (2026)
Aspirin may reduce CRC incidence slightly at follow-up ≥ 15 years (HR 0.78, 95% CI 0.67 to 0.91; 3 studies, 47,464 participants; very low-certainty evidence), but the evidence is very uncertain.
Regarding CRA incidence, aspirin may result in little to no difference in CRA incidence at ≥ 5 to < 10 years of follow-up (Peto OR 0.42, 95% CI 0.10 to 1.87; 1 study, 12,546 participants; very low certainty evidence), but the evidence is very uncertain.
It is not possible to draw definitive conclusions or outline specific implications for the routine use of aspirin for CRC primary prevention based on the current evidence.